Opioid Addiction

February 10, 2025

SPRAVATO® (Esketamine) Gains FDA Approval as the First Standalone Treatment for Adults with Treatment-Resistant Depression

January 21, 2025 – Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved SPRAVATO® (esketamine) CII…